盟科藥業(688373.SH):MRX-8中國I期臨牀試驗達到預期目標
格隆匯6月4日丨盟科藥業(688373.SH)公佈,公司自主研發的新型注射用多黏菌素類抗菌藥MRX-8的中國I期臨牀試驗已於近日完成並達到預期目標。
MRX-8是一種用於注射的多黏菌素類抗菌藥,主要用於治療多重耐藥的革蘭陰性菌感染。傳統的多黏菌素類藥物由於可導致多發的腎毒性和神經毒性,臨牀使用受限。MRX-8作為一種新型的多黏菌素類陽離子多肽藥物,經過精心的結構設計,在保持或改善治療效果的同時,有望降低多黏菌素抗菌藥的腎毒性和神經毒性的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.